AMD treatment with NeoVista system

Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, where they leak blood and fluid, causing scar tissue to form and vision to become impaired. With wet AMD, vision loss may occur faster and be more noticeable than with dry AMD. The longer the abnormal vessels leak or grow, the more detail vision will be lost. The earlier wet AMD is diagnosed, the better the patients' chance of preserving some or much of their central vision.

The first European patients have been treated for wet age-related macular degeneration with NeoVista's Vidion ANV Therapy System, an epimacular brachytherapy device that delivers a single dose of therapeutic radiation, the manufacturer announced in a press release.

Stanislao Rizzo, MD, of S. Chiara Hospital, Pisa, Italy, treated the initial group of patients with the Vidion ANV Therapy System. Unlike previous radiation therapies for wet AMD, NeoVista's innovative device delivers the peak dose of strontium-90 beta ionizing radiation directly to the lesion minimizing exposure to the surrounding tissue. The minimally invasive procedure utilizes a device similar in size to a needle, to deliver a highly targeted dose of radiation directly to the area of the retina affected by wet AMD. Importantly for patients, the systemic radiation exposure is minimal, as the effective dose to the entire body from NeoVista's epimacular brachytherapy device is less then a routine chest x-ray.

The Vidion system is undergoing phase 3 clinical trials for U.S. Food and Drug Administration marketing approval. The device proved safe and effective in preliminary clinical trials, the release said.